查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827877

生技藥品市場按產品類型、技術、給藥途徑、治療領域、最終用戶和分銷管道分類 - 全球預測 2025-2032

Biologics Market by Product Type, Technology, Route Of Administration, Therapeutic Area, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年生技藥品市場規模將成長至 7,191.7 億美元，複合年成長率為 6.62%。

主要市場統計數據
基準年2024年 4305.9億美元
預計2025年 4594.5億美元
預測年份：2032年 7191.7億美元
複合年成長率（%） 6.62%

簡潔、綜合地概述了當前生技藥品的動態、銜接科學創新、商業性壓力點以及領導者的營運重點

生技藥品處於尖端科學與複雜商業動態的交會點，正在重新定義多個治療領域的治療模式。本執行摘要整合了當前的結構性變化、監管和商業壓力、細分市場主導的機會以及區域考量，旨在為負責掌握近期策略格局的高層領導者提供清晰的敘述。本摘要匯集了平台創新、生產和分銷載體以及相關人員期望等方面的證據，旨在幫助高階主管明確投資、夥伴關係和營運協調的優先事項。

本書重點闡述了產品創新與大規模提供療法所需的生態系統之間的相互作用，涵蓋從上游研發技術到下游分銷管道的各個環節。本書也強調了政策、供應鏈韌性和付款人方式的變化如何重塑商業性路徑。本書的引言透過闡述關鍵訊號和實際意義，為後續章節奠定了基礎，這些章節旨在為參與生技藥品開發、生產和交付的組織提供高層策略和可操作的舉措。

科學、監管和營運的演變如何重塑生技藥品的開發、製造靈活性和商業化策略

在日趨成熟的技術、新的法律規範以及相關人員不斷變化的期望的推動下，生技藥品領域正在經歷重大變革。基因編輯技術的進步和平台的改進，正在將先前的實驗性方法推向更具臨床可行性的領域，從而加速了人們對罕見和複雜疾病的標靶治療方法的興趣。同時，製造模式正在轉向模組化、靈活的生產能力，以縮短前置作業時間並提高對臨床需求的應對力，從而改變了整個價值鏈的資本配置和夥伴關係關係。

不斷變化的政策和支付方正在為基於結果的合約和證據生成創造新的獎勵，這正在影響研究設計、核准後數據承諾和商業化策略。數位化工具和數據互通性正在增強患者參與度和分散式臨床試驗模式，從而實現更有效率的招募和更豐富的縱向證據。同時，供應鏈優先排序（包括原料採購、低溫運輸物流和生產冗餘）已成為營運的當務之急。總的來說，這些轉變既創造了差異化的機會，也帶來了重塑傳統經營模式的壓力，促使組織採用整合的跨職能方法，以協調研發、製造、法規事務和商業規劃。

評估 2025 年關稅如何改變生技藥品相關人員的供應鏈採購、區域產能決策與籌資策略

2025年實施的最新關稅為生技藥品相關人員帶來了額外的複雜性，影響了跨區域採購、生產佈局以及整個供應鏈的成本結構。針對特定投入、設備或成品生物製藥，促使許多公司重新評估籌資策略，深化與本地供應商的關係，並加速雙重採購以降低風險。這些調整需要更複雜的採購分析、重新協商供應商契約，並與物流合作夥伴更緊密地協調，以保持關鍵試劑和組件的連續性。

為了應對關稅帶來的不確定性，製造商重新審視了其產能分配決策和資本投資，並更加重視能夠服務重點市場並最大程度減少跨境摩擦的區域生產基地。監管機構和行業協會加強了對話，以明確分類規則並加快溫度敏感貨物的清關速度，從而減輕了部分營運負擔。同時，付款人和醫療保健提供者正密切關注潛在的下游成本影響，並引發了關於將關稅影響納入考慮的報銷框架和總醫療成本模型的討論。最終，2025年關稅的累積影響已將地緣政治考量提升至生技藥品公司策略規劃的核心要素，影響從研發地點選擇到商業化排序和夥伴關係結構的決策。

透過整合細分洞察推動策略協調，將產品模式、實行技術、交付途徑、治療重點、護理環境和分銷方法連結起來

細分領域的分析揭示了產品類型、技術、給藥途徑、治療領域、最終用戶和分銷管道之間的獨特動態，每種動態都需要不同的策略應對措施。按產品類型分類，血液因子產品、單株抗體、重組蛋白和疫苗等仍是基礎生物製藥類別，擁有成熟的生產和監管途徑；而細胞和基因療法則正從專業中心向更廣泛的商業網路發展。具體而言，細胞療法分為CAR-T療法和幹細胞療法，每種療法都有其獨特的開發途徑、生產限制和醫療服務模式，這些都會影響臨床部署策略。

同時，基因編輯技術（例如 CRISPR、TALEN 和鋅指核酸酶）為精準醫療提供了強大的選擇，但也引發了有關監管協調和長期監測的新考慮。不同的給藥途徑——肌肉注射、靜脈注射和皮下注射——決定了患者的獲取策略、低溫運輸需求和臨床經濟學。治療領域——自體免疫疾病、心血管疾病、感染疾病、代謝性疾病、神經系統疾病和腫瘤學——指導臨床開發的優先順序和證據生成路徑。最終使用者——診所、居家醫療服務、醫院和研究機構——決定了分銷、培訓和支援模式。最後，分銷管道的選擇——醫院藥房、線上通路或零售藥房——會影響履約方式、病患依從性舉措和商業夥伴關係設計。結合這些細分視角，可以提供一個實用的框架，使研發投資、製造設計和上市模式與每種治療方法和衛星群的固有需求保持一致。

在多樣化的全球醫療保健生態系統中協調製造、監管參與和商業化的區域要務和差異化策略

區域動態創造了獨特的機會和營運需求，需要採取差異化的市場准入、監管參與和生產力計畫方法。在美洲，成熟的臨床生態系統和先進的製造群持續吸引對複雜模式和後期開發的投資，而政策對話和付款人結構則影響商業化順序和證據要求。在該地區營運的公司通常優先考慮可擴展的生產和強大的上市後證據策略，以適應成熟的供應商網路和報銷模式。

在歐洲、中東和非洲，相關人員面臨部分地區成熟的法律規範，而其他地區則面臨產能受限的市場。監管協調工作和共用採購機制可以支援更廣泛的准入，但基礎設施和定價政策的差異使得靈活的商業性方式成為必要。亞太地區的條件高度多樣化，一些市場提供快速進入途徑並不斷提升臨床試驗能力，而另一些市場則專注於建立製造和監管能力。在許多亞太市場，優惠的政策獎勵和不斷成長的醫療保健需求正在推動企業加快技術轉移、建立本地夥伴關係關係和區域規模生產，以應對國內和出口機會。在所有地區，將製造地、監管參與和商業化模式與當地結構性現實相結合仍然是成功的關鍵。

領先的生技藥品公司如何結合夥伴關係、模組化製造和跨職能管治，以確保競爭性執行和價值交付

主要企業的生技藥品公司正透過策略夥伴關係關係、有針對性的產能投資和專注的產品組合開發等方式增強其競爭地位，並專注於平台擴充性和法規合規性。那些將內部能力與外部合作夥伴（例如合約生產企業 (CM​​O)、學術中心和利基技術提供者）進行策略性整合的公司，能夠更好地管理研發的複雜性，並加速從實驗室創新到臨床應用的轉化進程。對模組化製造和用於製程控制的高級分析的投資，使批次品質更加可預測，技術轉移速度更快，並已成為其獨特的營運能力。

同時，成功的公司正在積極與監管機構和付款方合作，共同設計能夠展現現實世界價值的證據生成策略，並在適當情況下協商獲得有條件核准或管理准入協議的途徑。商業成熟度也在不斷提高，領先的公司正在建立全面的患者支持生態系統和創新的分銷結構，以提升醫院、診所、居家照護機構、零售店和線上管道的覆蓋率。在技​​術創新日新月異、相關利益者期望不斷變化等背景下，人才培養和整合研發、製造、商業性團隊的跨職能管治結構正成為推動持續執行的關鍵相關人員。

為領導者提供實際的優先行動，以加強生技藥品供應鏈、監管參與、製造敏捷性和商業性準備

產業領導者應優先考慮一系列具體行動，以增強韌性、加速商業化進程，並在管理風險的同時獲得臨床價值。首先，將策略供應鏈審查納入企業規劃週期，以評估採購集中度，並明確區域產能擴張和雙重採購的標準。其次，在臨床生命週期的早期，將產品開發藍圖與監管機構和付款方的證據要求一致，以減少下游摩擦，並實現更靈活的商業化路徑。第三，投資模組化製造平台和數位化流程控制，以縮短技術轉移時間，並支持優先治療模式的快速擴展。

同時，建立嚴謹的夥伴關係策略，將內部優勢與先進技術、契約製造和專業臨床網路等外部能力結合，並正式建立包含共用資料標準和管治的合作。透過設計針對給藥途徑和最終用戶環境的分銷和患者支援計劃來強化商業模式，確保為醫院、診所、居家醫療和藥房管道提供適當的臨床培訓和供應連續性措施。最後，與監管機構保持適應性接觸，以預測政策變化，並儘早參與有關分類、核准途徑和上市後義務的對話。實施這些優先步驟將使公司能夠更靈活地應對地緣政治和技術變革，同時為持續的臨床和商業性影響鋪平道路。

我們的多方法研究途徑結合了專家訪談、技術文獻分析和商業案例審查，以提供基於證據的策略指導

本報告採用多種方法，整合了一手和二手研究，包括質性專家訪談、技術文獻綜述和營運案例分析。報告採訪了開發、製造、監管事務和商業策略領域的專家，以獲得關於平台採用、生產力計畫和相關人員的第一手觀點。報告也查閱了二手技術文獻和監管指導文件，以檢驗相關機制和合獎勵考量。該報告對近期技術轉移和供應鏈重組的營運案例進行了分析，提供了實施挑戰和緩解措施的實例。

數據整合強調了數據來源的可重複性和可追溯性，並記錄了分析步驟，以支持對主題觀察和含義的解釋。調查方法結合了基於情境的敏感性檢驗，以測試策略建議在不同政策和營運環境下的適應性。自始至終，我們致力於將實證洞見轉化為可供決策者操作的指導，同時公開證據的局限性，並清晰地指出哪些進一步的初步研究將有益於特定組織的決策。

綜合策略意義，強調生技藥品創新需要韌性、跨職能編配與能力投資

生技藥品領域正處於曲折點，科學突破與複雜的商業性現實交織在一起，既帶來了高期望，也帶來了日益成長的營運需求。積極擁抱供應鏈韌性、監管和付款人參與、生產敏捷性以及細分主導的商業化的組織，最有能力將科學進步轉化為患者效益和永續的業務成果。基因編輯和模組化製造等技術進步拓展了可行的治療策略。

未來的成功將取決於各組織協調跨職能能力、建立務實夥伴關係關係以及採用能夠反映當地監管和醫療服務環境的循證商業化模式的能力。相關人員應將當前環境視為重塑傳統營運模式的機遇，並投資於支持快速可靠地交付複雜生技藥品的能力。這樣做將有助於緩解短期中斷，並抓住下一波生技藥品創新浪潮帶來的長期臨床和商業性利益。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 主要醫藥市場迅速採用生物相似藥互換性指南，推動價格競爭
  • 引入一次性生物反應器技術，縮短開發時間並降低交叉污染風險
  • 整合單株抗體生產的連續製造程序，以提高可擴展性並降低成本
  • 利用針對罕見遺傳疾病的新型病毒載體平台擴展基因治療產品線
  • 應用人工智慧驅動的細胞株開發來最佳化克隆選擇並提高生物過程產量
  • 生物製藥公司與CDMO之間的策略合作夥伴關係拓展了高效生技藥品和基因療法的能力
  • 主要市場的監管協調將加速生物相似藥和下一代生物療法的全球核准
  • 增加對蛋白質療法新型遞送平台的投資，以提高患者依從性和藥物動力學

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章生技藥品市場（依產品類型）

  • 血液因子產品
  • 細胞療法
    • CAR-T療法
    • 幹細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第9章生技藥品市場（依技術）

  • 細胞培養技術
  • 基因編輯技術
    • CRISPR
    • TALENs
    • 鋅指核酸酶
  • 融合瘤技術
  • 重組DNA技術

第10章生技藥品市場（依給藥途徑）

  • 肌肉注射
  • 靜脈
  • 皮下

第 11 章生技藥品市場（依治療領域）

  • 自體免疫
  • 心血管疾病
  • 感染疾病
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤學

第 12 章生技藥品市場（依最終使用者）

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究機構

第13章生技藥品市場（依通路）

  • 醫院藥房
  • 線上管道
  • 零售藥局

第14章生技藥品市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章生技藥品市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國生技藥品市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Roche Holding AG
    • AbbVie Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi SA
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
Product Code: MRR-4302AC72200D

The Biologics Market is projected to grow by USD 719.17 billion at a CAGR of 6.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 430.59 billion
Estimated Year [2025] USD 459.45 billion
Forecast Year [2032] USD 719.17 billion
CAGR (%) 6.62%

A concise, integrated overview of current biologics dynamics bridging scientific innovation, commercial pressure points, and operational priorities for leaders

Biologics sit at the intersection of advanced science and complex commercial dynamics, redefining treatment paradigms across multiple therapeutic areas. This executive summary synthesizes current structural shifts, regulatory and trade pressures, segmentation-driven opportunities, and regional considerations to provide a coherent narrative for senior leaders tasked with navigating the near-term strategic landscape. It brings together evidence on platform innovations, manufacturing and distribution vectors, and stakeholder expectations so that executives can prioritize investments, partnerships, and operational adjustments with clarity.

The narrative emphasizes the interplay between product innovation and the ecosystems required to deliver therapies at scale, from upstream R&D technologies through to downstream distribution channels. It highlights how changes in policy, supply chain resilience, and payer approaches are reshaping commercial pathways. By framing the key signals and practical implications, the introduction sets a foundation for reading subsequent sections as a connected set of insights intended to inform both high-level strategy and actionable initiatives within organizations active across biologics development, production, and delivery.

How convergent scientific, regulatory, and operational evolutions are reshaping biologics development, manufacturing flexibility, and commercialization strategies

The biologics landscape is undergoing transformative shifts driven by converging technological maturation, new regulatory frameworks, and evolving stakeholder expectations. Gene editing advancements and platform refinement have pushed previously experimental approaches into more clinically viable territories, accelerating interest in therapies that target rare and complex conditions. At the same time, manufacturing paradigms are shifting toward modular, flexible capacity to reduce lead times and increase responsiveness to clinical demand, altering capital allocation and partnership calculus across the value chain.

Policy and payer evolution are creating fresh incentives for outcome-based contracting and evidence generation, which in turn influence trial design, post-approval data commitments, and commercialization strategies. Digital tools and data interoperability are enhancing patient engagement and decentralized trial models, enabling more efficient recruitment and richer longitudinal evidence. Meanwhile, supply chain prioritization-spanning raw material sourcing, cold-chain logistics, and production redundancy-has become an operational imperative. These shifts collectively create both opportunities for differentiation and pressure to reconfigure traditional business models, encouraging organizations to adopt integrated cross-functional approaches that align R&D, manufacturing, regulatory affairs, and commercial planning.

Assessing how 2025 tariff measures have altered supply chain sourcing, regional capacity decisions, and procurement strategies for biologics stakeholders

Recent tariff actions instituted in 2025 introduced an additional layer of complexity for biologics stakeholders, affecting multi-jurisdictional procurement, manufacturing footprints, and cost structures across supply chains. Tariff measures that target specific inputs, equipment, or finished biologic products have prompted many organizations to reassess sourcing strategies, deepen local supplier relationships, and accelerate dual-sourcing initiatives to mitigate exposure. These adjustments have required more sophisticated procurement analytics, renegotiation of supplier contracts, and closer coordination with logistics partners to preserve continuity of critical reagent and component flows.

In response to tariff-driven uncertainties, manufacturers have also revisited capacity allocation decisions and capital investments, placing greater emphasis on regional production nodes that can serve priority markets with minimal cross-border friction. Regulatory authorities and industry groups have increasingly engaged in dialogue to clarify classification rules and to expedite customs procedures for temperature-sensitive shipments, which has eased some operational burdens. Simultaneously, payers and providers are attentive to potential downstream cost implications, prompting discussions about reimbursement frameworks and total-cost-of-care models that account for tariff effects. Ultimately, the cumulative impact of the 2025 tariff measures has elevated geopolitical considerations as a core element of strategic planning for biologics companies, influencing decisions from R&D site selection to commercialization sequencing and partnership structuring.

Integrated segmentation insights linking product modalities, enabling technologies, delivery pathways, therapeutic focuses, care settings, and distribution approaches for strategic alignment

Segment-level analysis reveals differentiated dynamics across product types, technologies, routes of administration, therapeutic areas, end users, and distribution channels, each demanding distinct strategic responses. Within product typologies, modalities such as blood factor products, monoclonal antibodies, recombinant proteins, and vaccines continue to represent foundational biologic classes with established manufacturing and regulatory pathways, while cell therapies and gene therapies are advancing from specialized centers toward broader commercial networks. Cell therapies specifically bifurcate into CAR-T therapies and stem cell therapies, each with unique development pathways, manufacturing constraints, and care-delivery models that affect clinical rollout strategies.

On the technology axis, the adoption and integration of cell culture platforms, hybridoma methods, and recombinant DNA approaches remain critical to optimizing yield and quality, whereas gene editing technology-comprising CRISPR, TALENs, and zinc finger nucleases-introduces powerful options for precision modalities but also raises new considerations around regulatory harmonization and long-term surveillance. Route-of-administration distinctions between intramuscular, intravenous, and subcutaneous delivery shape patient access strategies, cold-chain requirements, and site-of-care economics. Therapeutic area focus across autoimmune, cardiovascular diseases, infectious diseases, metabolic disorders, neurological disorders, and oncology directs clinical development prioritization and evidence generation pathways, while end users such as clinics, home healthcare services, hospitals, and research institutes determine distribution, training, and support models. Finally, distribution channel selection among hospital pharmacies, online channels, and retail pharmacies impacts fulfillment approaches, patient adherence initiatives, and the design of commercial partnerships. Taken together, these segmentation lenses provide a practical framework for aligning R&D investments, manufacturing design, and go-to-market models with the intrinsic needs of each therapeutic and delivery constellation.

Regional imperatives and differentiated strategies for aligning manufacturing, regulatory engagement, and commercialization across diverse global healthcare ecosystems

Regional dynamics are creating distinct opportunity contours and operational imperatives that require differentiated approaches to market entry, regulatory engagement, and capacity planning. In the Americas, established clinical ecosystems and advanced manufacturing clusters continue to attract investment in complex modalities and late-stage development, while policy dialogues and payer structures influence commercialization sequencing and evidence demands. Companies operating in this region frequently prioritize scalable manufacturing and robust post-market evidence strategies to align with sophisticated provider networks and reimbursement models.

Across Europe, the Middle East & Africa, stakeholders face a mix of mature regulatory frameworks in parts of Europe and capacity-constrained markets elsewhere, which encourages strategies that combine regional manufacturing hubs with tailored distribution partnerships. Regulatory harmonization efforts and shared procurement mechanisms can support wider access, but variations in infrastructure and pricing policies necessitate flexible commercial approaches. The Asia-Pacific region presents a highly heterogeneous set of conditions, with some markets offering rapid adoption pathways and growing clinical trial capacity while others focus on building manufacturing and regulatory capabilities. In many Asia-Pacific markets, favorable policy incentives and expanding healthcare demand are leading firms to accelerate technology transfer, local partnership formation, and regionally scaled production to serve both domestic and export opportunities. Across all regions, aligning manufacturing footprint, regulatory engagement, and commercialization models to local structural realities remains essential for success.

How leading biologics organizations are combining partnerships, modular manufacturing, and cross-functional governance to secure competitive execution and value delivery

Leading companies in the biologics space are consolidating their competitive positions through a blend of strategic partnerships, targeted capacity investments, and focused portfolio development that emphasizes platform scalability and regulatory readiness. Firms that strategically align their internal capabilities with external collaborators-such as CMOs, academic centers, and niche technology providers-are better positioned to manage development complexity and to accelerate translational pathways from laboratory innovations to clinical applications. Investment in modular manufacturing and advanced analytics for process control has become a distinguishing operational capability, enabling more predictable batch quality and faster tech transfer.

In parallel, successful organizations are proactively engaging regulators and payers to co-design evidence-generation strategies that demonstrate real-world value and to negotiate pathways for conditional approvals or managed-entry agreements where appropriate. Commercial sophistication is also rising, with leading players building comprehensive patient support ecosystems and innovative distribution arrangements to enhance uptake across hospitals, clinics, home care settings, and retail or online channels. Talent development and cross-functional governance structures that integrate R&D, manufacturing, regulatory affairs, and commercial teams are emerging as critical enablers for sustained execution in a landscape characterized by rapid technological change and evolving stakeholder expectations.

Practical and prioritized actions for leaders to strengthen supply chains, regulatory alignment, manufacturing agility, and commercial readiness in biologics

Industry leaders should prioritize a sequence of concrete actions designed to strengthen resilience, accelerate commercialization, and capture clinical value while managing risk. First, integrate strategic supply chain reviews into corporate planning cycles to assess sourcing concentration and to define criteria for regional capacity expansion and dual sourcing. Second, align product development roadmaps with regulatory and payer evidence requirements early in the clinical lifecycle to reduce downstream friction and to enable more flexible commercialization pathways. Third, invest in modular manufacturing platforms and digital process controls that reduce tech transfer timelines and support rapid scale-up for high-priority modalities.

In parallel, cultivate a disciplined partnership strategy that pairs internal strengths with external capabilities in advanced technologies, contract manufacturing, or specialized clinical networks, and formalize collaboration frameworks that include shared data standards and governance. Strengthen commercial models by designing distribution and patient-support programs tailored to route of administration and end-user settings, ensuring that hospital, clinic, home care, and pharmacy channels are each supported with appropriate clinical training and supply continuity measures. Finally, maintain an adaptive regulatory engagement posture to anticipate policy shifts and to participate in early dialogues on classification, approval pathways, and post-market obligations. Executing these prioritized steps will position organizations to respond more nimbly to geopolitical and technological disruptions while unlocking pathways to sustained clinical and commercial impact.

A multi-method research approach combining expert interviews, technical literature analysis, and operational case reviews to produce evidence-driven strategic guidance

This report synthesizes primary and secondary research inputs, structured around a multi-method approach that triangulates qualitative expert interviews, technical literature review, and operational case analysis to ensure robust, evidence-driven conclusions. Interviews were conducted with subject-matter experts across development, manufacturing, regulatory affairs, and commercial strategy to capture first-hand perspectives on platform adoption, capacity planning, and stakeholder incentives. Secondary technical literature and regulatory guidance documents were examined to validate mechanistic and compliance considerations, while operational case analyses of recent technology transfers and supply chain reconfigurations provided practical illustrations of execution challenges and mitigations.

Data synthesis emphasized reproducibility and traceability of sources, with analytic steps documented to support interpretation of thematic findings and implications. The methodology incorporated scenario-based sensitivity checks to test the resilience of strategic recommendations under differing policy and operational conditions. Throughout, the emphasis remained on translating empirical insights into actionable guidance for decision-makers, with transparency about evidence limitations and clear signposts for where further primary investigation would be valuable for organization-specific decisions.

Synthesis of strategic implications highlighting the need for resilience, cross-functional orchestration, and capability investments to capture biologics innovation

The biologics field is at an inflection point where scientific breakthroughs and complex commercial realities intersect, creating both significant promise and heightened operational demands. Organizations that proactively address supply chain resilience, regulatory and payer engagement, manufacturing agility, and segmentation-driven commercialization will be best positioned to translate scientific advances into patient impact and sustainable business outcomes. The cumulative effects of recent trade and policy shifts underscore the necessity of integrating geopolitical risk into core strategic decisions, while technology advances such as gene editing and modular manufacturing expand the palette of viable therapeutic strategies.

Moving forward, success will hinge on an organization's ability to orchestrate cross-functional capabilities, to form pragmatic partnerships, and to adopt evidence-centered commercialization models that reflect local regulatory and delivery contexts. Stakeholders should view the current environment as an opportunity to reconfigure traditional operating models and to invest in capabilities that support faster, more reliable delivery of complex biologics. By doing so, they can both mitigate short-term disruptions and position themselves to capture the long-term clinical and commercial benefits arising from the next wave of biologics innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of biosimilar interchangeability guidelines within major pharmaceutical markets driving competitive pricing
  • 5.2. Implementation of single-use bioreactor technologies to accelerate development timelines and reduce cross-contamination risks
  • 5.3. Integration of continuous manufacturing processes in monoclonal antibody production to enhance scalability and reduce costs
  • 5.4. Expansion of gene therapy biologics pipelines with novel viral vector platforms targeting rare genetic disorders
  • 5.5. Application of AI-driven cell line development to optimize clone selection and improve bioprocess yields
  • 5.6. Strategic partnerships between biopharma companies and CDMOs to expand capacity for high-potency biologics and gene therapies
  • 5.7. Regulatory alignment across major markets facilitating global approvals of biosimilar and next-generation biologic therapies
  • 5.8. Growing investment in novel delivery platforms for protein therapeutics to improve patient adherence and pharmacokinetics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Market, by Product Type

  • 8.1. Blood Factor Products
  • 8.2. Cell Therapies
    • 8.2.1. CAR-T Therapies
    • 8.2.2. Stem Cell Therapy
  • 8.3. Gene Therapies
  • 8.4. Monoclonal Antibodies
  • 8.5. Recombinant Proteins
  • 8.6. Vaccines

9. Biologics Market, by Technology

  • 9.1. Cell Culture Technology
  • 9.2. Gene Editing Technology
    • 9.2.1. CRISPR
    • 9.2.2. TALENs
    • 9.2.3. Zinc Finger Nucleases
  • 9.3. Hybridoma Technology
  • 9.4. Recombinant DNA Technology

10. Biologics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Biologics Market, by Therapeutic Area

  • 11.1. Autoimmune
  • 11.2. Cardiovascular Diseases
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Oncology

12. Biologics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Biologics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Channel
  • 13.3. Retail Pharmacy

14. Biologics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Roche Holding AG
    • 17.3.2. AbbVie Inc.
    • 17.3.3. Pfizer Inc.
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Novartis AG
    • 17.3.6. Merck & Co., Inc.
    • 17.3.7. Sanofi S.A.
    • 17.3.8. Amgen Inc.
    • 17.3.9. Bristol-Myers Squibb Company
    • 17.3.10. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 347. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 348. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 349. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 351. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. GLOBAL